

091-25618h

For Internal Use
Only
Sec File No. 9-

Submit 1 Original
and 9 Copies

OMB APPROVAL

OMB Number: 3235-0504
Expires: August 31, 2010
Estimated average burden
hours per response: 3.60

RECEIVED
2018 SEP 11 PM 4:34
SEC / TM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 19b-4(e)

Information Required of a Self-Regulatory Organization Listing and Trading a New
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM

SEC
Mail Processing
Section
SEP 11 2018
Washington DC
410

Part I Initial Listing Report

- Name of Self-Regulatory Organization Listing New Derivative Securities Product:
Nasdaq Stock Market LLC (traded pursuant to unlisted trading privileges)
- Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):
Open End Management Investment Company
- Class of New Derivative Securities Product:
Exchange Traded Fund
- Name of Underlying Instrument:
Solactive Emerging Markets Healthcare Index
- If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:
Broad-based
- Ticker Symbol(s) of New Derivative Securities Product:
KMED
- Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:
Listed on: Abu Dhabi , Alexandria, Athens, Bangkok, Bogota, Bovespa, Budapest, Bursa Malaysia, Cairo, Indonesia, Istanbul Stock Exchange, Johannesburg Stock Exchange, Lima Stock Exchange, Mexican Stock Exchange, Moscow, National Stock Exchange Of India, Philippine Stock Exchange, Prague, Qatar, Santiago Stock Exchange, Shanghai Stock Exchange, Shenzhen, Warsaw
- Position Limits of New Derivative Securities Product (if applicable):
Regular way trades settle on T + 2 (cash settled)
- Position Limits of New Derivative Securities Product (if applicable):
N/A

Part II Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:
William Slattery

Title:
Vice President

Telephone Number:
+1 301 9788088

Signature of Official Responsible for Form:

Date: **September 07, 2018**



18010457

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability	SEP 11 2018